APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non Hodgkin Lymphoma (NHL)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Non Hodgkin Lymphoma (NHL) Market Analysis and Forecast 2026-2032

20 December 2025197 pages

Choose your research edition.

Industry ResearchNon Hodgkin Lymphoma (NHL) Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Non Hodgkin Lymphoma (NHL) Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Non Hodgkin Lymphoma (NHL) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non Hodgkin Lymphoma (NHL) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Non Hodgkin Lymphoma (NHL) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Non Hodgkin Lymphoma (NHL) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Non Hodgkin Lymphoma (NHL) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Non Hodgkin Lymphoma (NHL) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Non Hodgkin Lymphoma (NHL) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Non Hodgkin Lymphoma (NHL) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Non Hodgkin Lymphoma (NHL) include Bristol Myers Squibb, Celgene, F. Hoffmann-La Roche, Bayer, GlaxoSmithKline, Eli Lilly, Merck and Johnson & Johnson, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Non Hodgkin Lymphoma (NHL), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Non Hodgkin Lymphoma (NHL), also provides the revenue of main regions and countries. Of the upcoming market potential for Non Hodgkin Lymphoma (NHL), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Non Hodgkin Lymphoma (NHL) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Non Hodgkin Lymphoma (NHL) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Non Hodgkin Lymphoma (NHL) revenue, projected growth trends, production technology, application and end-user industry.

Non Hodgkin Lymphoma (NHL) Segment by Company

Bristol Myers Squibb

Celgene

F. Hoffmann-La Roche

Bayer

GlaxoSmithKline

Eli Lilly

Merck

Johnson & Johnson

Non Hodgkin Lymphoma (NHL) Segment by Type

Standard

Exellent

Non Hodgkin Lymphoma (NHL) Segment by Application

Hosptial

Clinic

Non Hodgkin Lymphoma (NHL) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non Hodgkin Lymphoma (NHL) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non Hodgkin Lymphoma (NHL) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non Hodgkin Lymphoma (NHL).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Non Hodgkin Lymphoma (NHL) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Non Hodgkin Lymphoma (NHL) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non Hodgkin Lymphoma (NHL) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Standard Major Player Table 3. Exellent Major Player Table 4. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hosptial Major Player Table 6. Clinic Major Player Table 7. Non Hodgkin Lymphoma (NHL) Industry Trends Table 8. Non Hodgkin Lymphoma (NHL) Industry Drivers Table 9. Non Hodgkin Lymphoma (NHL) Industry Opportunities and Challenges Table 10. Non Hodgkin Lymphoma (NHL) Industry Restraints Table 11. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Non Hodgkin Lymphoma (NHL) Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Non Hodgkin Lymphoma (NHL) Market Share by Region (2021-2026) Table 14. Global Non Hodgkin Lymphoma (NHL) Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Non Hodgkin Lymphoma (NHL) Market Share by Region (2027-2032) Table 16. Global Non Hodgkin Lymphoma (NHL) Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Players (2021-2026) Table 18. Global Non Hodgkin Lymphoma (NHL) Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Non Hodgkin Lymphoma (NHL) Key Players Headquarters & Area Served Table 20. Global Non Hodgkin Lymphoma (NHL) Players, Product Type & Application Table 21. Global Non Hodgkin Lymphoma (NHL) Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Non Hodgkin Lymphoma (NHL) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Non Hodgkin Lymphoma (NHL) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Non Hodgkin Lymphoma (NHL) Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2021-2026) Table 28. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2027-2032) Table 29. Global Non Hodgkin Lymphoma (NHL) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Non Hodgkin Lymphoma (NHL) Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2021-2026) Table 33. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2027-2032) Table 34. Bristol Myers Squibb Company Information Table 35. Bristol Myers Squibb Business Overview Table 36. Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Product Portfolio Table 38. Bristol Myers Squibb Recent Development Table 39. Celgene Company Information Table 40. Celgene Business Overview Table 41. Celgene Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Celgene Non Hodgkin Lymphoma (NHL) Product Portfolio Table 43. Celgene Recent Development Table 44. F. Hoffmann-La Roche Company Information Table 45. F. Hoffmann-La Roche Business Overview Table 46. F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Product Portfolio Table 48. F. Hoffmann-La Roche Recent Development Table 49. Bayer Company Information Table 50. Bayer Business Overview Table 51. Bayer Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Bayer Non Hodgkin Lymphoma (NHL) Product Portfolio Table 53. Bayer Recent Development Table 54. GlaxoSmithKline Company Information Table 55. GlaxoSmithKline Business Overview Table 56. GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Product Portfolio Table 58. GlaxoSmithKline Recent Development Table 59. Eli Lilly Company Information Table 60. Eli Lilly Business Overview Table 61. Eli Lilly Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Eli Lilly Non Hodgkin Lymphoma (NHL) Product Portfolio Table 63. Eli Lilly Recent Development Table 64. Merck Company Information Table 65. Merck Business Overview Table 66. Merck Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Merck Non Hodgkin Lymphoma (NHL) Product Portfolio Table 68. Merck Recent Development Table 69. Johnson & Johnson Company Information Table 70. Johnson & Johnson Business Overview Table 71. Johnson & Johnson Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Johnson & Johnson Non Hodgkin Lymphoma (NHL) Product Portfolio Table 73. Johnson & Johnson Recent Development Table 74. North America Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2026) & (US$ Million) Table 75. North America Non Hodgkin Lymphoma (NHL) Revenue by Type (2027-2032) & (US$ Million) Table 76. North America Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2026) & (US$ Million) Table 77. North America Non Hodgkin Lymphoma (NHL) Revenue by Application (2027-2032) & (US$ Million) Table 78. North America Non Hodgkin Lymphoma (NHL) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. North America Non Hodgkin Lymphoma (NHL) Revenue by Country (2021-2026) & (US$ Million) Table 80. North America Non Hodgkin Lymphoma (NHL) Revenue by Country (US$ Million) & (2027-2032) Table 81. Europe Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2026) & (US$ Million) Table 82. Europe Non Hodgkin Lymphoma (NHL) Revenue by Type (2027-2032) & (US$ Million) Table 83. Europe Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2026) & (US$ Million) Table 84. Europe Non Hodgkin Lymphoma (NHL) Revenue by Application (2027-2032) & (US$ Million) Table 85. Europe Non Hodgkin Lymphoma (NHL) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. Europe Non Hodgkin Lymphoma (NHL) Revenue by Country (2021-2026) & (US$ Million) Table 87. Europe Non Hodgkin Lymphoma (NHL) Revenue by Country (US$ Million) & (2027-2032) Table 88. China Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2026) & (US$ Million) Table 89. China Non Hodgkin Lymphoma (NHL) Revenue by Type (2027-2032) & (US$ Million) Table 90. China Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2026) & (US$ Million) Table 91. China Non Hodgkin Lymphoma (NHL) Revenue by Application (2027-2032) & (US$ Million) Table 92. Asia Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2026) & (US$ Million) Table 93. Asia Non Hodgkin Lymphoma (NHL) Revenue by Type (2027-2032) & (US$ Million) Table 94. Asia Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2026) & (US$ Million) Table 95. Asia Non Hodgkin Lymphoma (NHL) Revenue by Application (2027-2032) & (US$ Million) Table 96. Asia Non Hodgkin Lymphoma (NHL) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Asia Non Hodgkin Lymphoma (NHL) Revenue by Region (US$ Million) & (2021-2026) Table 98. Asia Non Hodgkin Lymphoma (NHL) Revenue by Region (US$ Million) & (2027-2032) Table 99. SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2026) & (US$ Million) Table 100. SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Type (2027-2032) & (US$ Million) Table 101. SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2026) & (US$ Million) Table 102. SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Application (2027-2032) & (US$ Million) Table 103. SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Country (2021-2026) & (US$ Million) Table 105. SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Country (US$ Million) & (2027-2032) Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Non Hodgkin Lymphoma (NHL) Image Figure 2. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non Hodgkin Lymphoma (NHL) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Standard Image Figure 5. Exellent Image Figure 6. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Non Hodgkin Lymphoma (NHL) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hosptial Image Figure 9. Clinic Image Figure 10. Global Non Hodgkin Lymphoma (NHL) Market Size (US$ Million) & (2021-2032) Figure 11. Global Non Hodgkin Lymphoma (NHL) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Non Hodgkin Lymphoma (NHL) Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Non Hodgkin Lymphoma (NHL) Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Non Hodgkin Lymphoma (NHL) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2021-2032) Figure 18. Global Non Hodgkin Lymphoma (NHL) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2021-2032) Figure 21. North America Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Non Hodgkin Lymphoma (NHL) Revenue Share by Type (2021-2032) Figure 23. North America Non Hodgkin Lymphoma (NHL) Revenue Share by Application (2021-2032) Figure 24. North America Non Hodgkin Lymphoma (NHL) Revenue Share by Country (2021-2032) Figure 25. United States Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Non Hodgkin Lymphoma (NHL) Revenue Share by Type (2021-2032) Figure 30. Europe Non Hodgkin Lymphoma (NHL) Revenue Share by Application (2021-2032) Figure 31. Europe Non Hodgkin Lymphoma (NHL) Revenue Share by Country (2021-2032) Figure 32. Germany Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Non Hodgkin Lymphoma (NHL) Revenue Share by Type (2021-2032) Figure 42. China Non Hodgkin Lymphoma (NHL) Revenue Share by Application (2021-2032) Figure 43. Asia Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Non Hodgkin Lymphoma (NHL) Revenue Share by Type (2021-2032) Figure 45. Asia Non Hodgkin Lymphoma (NHL) Revenue Share by Application (2021-2032) Figure 46. Asia Non Hodgkin Lymphoma (NHL) Revenue Share by Region (2021-2032) Figure 47. Japan Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Non Hodgkin Lymphoma (NHL) Revenue Share by Type (2021-2032) Figure 55. SAMEA Non Hodgkin Lymphoma (NHL) Revenue Share by Application (2021-2032) Figure 56. SAMEA Non Hodgkin Lymphoma (NHL) Revenue Share by Country (2021-2032) Figure 57. Brazil Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Non Hodgkin Lymphoma (NHL) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Standard
  • Exellent
Applications
  • Hosptial
  • Clinic
Companies covered
  • Bristol Myers Squibb
  • Celgene
  • F. Hoffmann-La Roche
  • Bayer
  • GlaxoSmithKline
  • Eli Lilly
  • Merck
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Non Hodgkin Lymphoma (NHL) Market by Type
  3. 1.2.1 Global Non Hodgkin Lymphoma (NHL) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Standard
  5. 1.2.3 Exellent
  6. 1.3 Non Hodgkin Lymphoma (NHL) Market by Application
  7. 1.3.1 Global Non Hodgkin Lymphoma (NHL) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hosptial
  9. 1.3.3 Clinic
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Non Hodgkin Lymphoma (NHL) Market Dynamics
  1. 2.1 Non Hodgkin Lymphoma (NHL) Industry Trends
  2. 2.2 Non Hodgkin Lymphoma (NHL) Industry Drivers
  3. 2.3 Non Hodgkin Lymphoma (NHL) Industry Opportunities and Challenges
  4. 2.4 Non Hodgkin Lymphoma (NHL) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Non Hodgkin Lymphoma (NHL) Market Perspective (2021-2032)
  2. 3.2 Global Non Hodgkin Lymphoma (NHL) Growth Trends by Region
  3. 3.2.1 Global Non Hodgkin Lymphoma (NHL) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Non Hodgkin Lymphoma (NHL) Market Size by Region (2021-2026)
  5. 3.2.3 Global Non Hodgkin Lymphoma (NHL) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Non Hodgkin Lymphoma (NHL) Revenue by Players
  2. 4.1.1 Global Non Hodgkin Lymphoma (NHL) Revenue by Players (2021-2026)
  3. 4.1.2 Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Non Hodgkin Lymphoma (NHL) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Non Hodgkin Lymphoma (NHL) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Non Hodgkin Lymphoma (NHL) Key Players Headquarters & Area Served
  7. 4.4 Global Non Hodgkin Lymphoma (NHL) Players, Product Type & Application
  8. 4.5 Global Non Hodgkin Lymphoma (NHL) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Non Hodgkin Lymphoma (NHL) Market CR5 and HHI
  11. 4.6.3 2025 Non Hodgkin Lymphoma (NHL) Tier 1, Tier 2, and Tier 3
5 Non Hodgkin Lymphoma (NHL) Market Size by Type
  1. 5.1 Global Non Hodgkin Lymphoma (NHL) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2032)
  3. 5.3 Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2021-2032)
6 Non Hodgkin Lymphoma (NHL) Market Size by Application
  1. 6.1 Global Non Hodgkin Lymphoma (NHL) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2032)
  3. 6.3 Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol Myers Squibb
  2. 7.1.1 Bristol Myers Squibb Company Information
  3. 7.1.2 Bristol Myers Squibb Business Overview
  4. 7.1.3 Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Product Portfolio
  6. 7.1.5 Bristol Myers Squibb Recent Developments
  7. 7.2 Celgene
  8. 7.2.1 Celgene Company Information
  9. 7.2.2 Celgene Business Overview
  10. 7.2.3 Celgene Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Celgene Non Hodgkin Lymphoma (NHL) Product Portfolio
  12. 7.2.5 Celgene Recent Developments
  13. 7.3 F. Hoffmann-La Roche
  14. 7.3.1 F. Hoffmann-La Roche Company Information
  15. 7.3.2 F. Hoffmann-La Roche Business Overview
  16. 7.3.3 F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Product Portfolio
  18. 7.3.5 F. Hoffmann-La Roche Recent Developments
  19. 7.4 Bayer
  20. 7.4.1 Bayer Company Information
  21. 7.4.2 Bayer Business Overview
  22. 7.4.3 Bayer Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bayer Non Hodgkin Lymphoma (NHL) Product Portfolio
  24. 7.4.5 Bayer Recent Developments
  25. 7.5 GlaxoSmithKline
  26. 7.5.1 GlaxoSmithKline Company Information
  27. 7.5.2 GlaxoSmithKline Business Overview
  28. 7.5.3 GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Product Portfolio
  30. 7.5.5 GlaxoSmithKline Recent Developments
  31. 7.6 Eli Lilly
  32. 7.6.1 Eli Lilly Company Information
  33. 7.6.2 Eli Lilly Business Overview
  34. 7.6.3 Eli Lilly Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Eli Lilly Non Hodgkin Lymphoma (NHL) Product Portfolio
  36. 7.6.5 Eli Lilly Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck Non Hodgkin Lymphoma (NHL) Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 Johnson & Johnson
  44. 7.8.1 Johnson & Johnson Company Information
  45. 7.8.2 Johnson & Johnson Business Overview
  46. 7.8.3 Johnson & Johnson Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Johnson & Johnson Non Hodgkin Lymphoma (NHL) Product Portfolio
  48. 7.8.5 Johnson & Johnson Recent Developments
8 North America
  1. 8.1 North America Non Hodgkin Lymphoma (NHL) Revenue (2021-2032)
  2. 8.2 North America Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2032)
  3. 8.2.1 North America Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2026)
  4. 8.2.2 North America Non Hodgkin Lymphoma (NHL) Revenue by Type (2027-2032)
  5. 8.3 North America Non Hodgkin Lymphoma (NHL) Revenue Share by Type (2021-2032)
  6. 8.4 North America Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2032)
  7. 8.4.1 North America Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2026)
  8. 8.4.2 North America Non Hodgkin Lymphoma (NHL) Revenue by Application (2027-2032)
  9. 8.5 North America Non Hodgkin Lymphoma (NHL) Revenue Share by Application (2021-2032)
  10. 8.6 North America Non Hodgkin Lymphoma (NHL) Revenue by Country
  11. 8.6.1 North America Non Hodgkin Lymphoma (NHL) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Non Hodgkin Lymphoma (NHL) Revenue by Country (2021-2026)
  13. 8.6.3 North America Non Hodgkin Lymphoma (NHL) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Non Hodgkin Lymphoma (NHL) Revenue (2021-2032)
  2. 9.2 Europe Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Non Hodgkin Lymphoma (NHL) Revenue by Type (2027-2032)
  5. 9.3 Europe Non Hodgkin Lymphoma (NHL) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Non Hodgkin Lymphoma (NHL) Revenue by Application (2027-2032)
  9. 9.5 Europe Non Hodgkin Lymphoma (NHL) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Non Hodgkin Lymphoma (NHL) Revenue by Country
  11. 9.6.1 Europe Non Hodgkin Lymphoma (NHL) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Non Hodgkin Lymphoma (NHL) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Non Hodgkin Lymphoma (NHL) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Non Hodgkin Lymphoma (NHL) Revenue (2021-2032)
  2. 10.2 China Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2032)
  3. 10.2.1 China Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2026)
  4. 10.2.2 China Non Hodgkin Lymphoma (NHL) Revenue by Type (2027-2032)
  5. 10.3 China Non Hodgkin Lymphoma (NHL) Revenue Share by Type (2021-2032)
  6. 10.4 China Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2032)
  7. 10.4.1 China Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2026)
  8. 10.4.2 China Non Hodgkin Lymphoma (NHL) Revenue by Application (2027-2032)
  9. 10.5 China Non Hodgkin Lymphoma (NHL) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Non Hodgkin Lymphoma (NHL) Revenue (2021-2032)
  2. 11.2 Asia Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Non Hodgkin Lymphoma (NHL) Revenue by Type (2027-2032)
  5. 11.3 Asia Non Hodgkin Lymphoma (NHL) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Non Hodgkin Lymphoma (NHL) Revenue by Application (2027-2032)
  9. 11.5 Asia Non Hodgkin Lymphoma (NHL) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Non Hodgkin Lymphoma (NHL) Revenue by Country
  11. 11.6.1 Asia Non Hodgkin Lymphoma (NHL) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Non Hodgkin Lymphoma (NHL) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Non Hodgkin Lymphoma (NHL) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Non Hodgkin Lymphoma (NHL) Revenue (2021-2032)
  2. 12.2 SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Non Hodgkin Lymphoma (NHL) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Non Hodgkin Lymphoma (NHL) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Country
  11. 12.6.1 SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Non Hodgkin Lymphoma (NHL) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst